BioCentury
ARTICLE | Clinical News

ALLN-177: Phase II started

February 15, 2016 8:00 AM UTC

Allena began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 7,500 units of oral ALLN-177 thrice daily with meals for 28 days in about 44 patients. ...